Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVNS-001
- Development stage
- Unknown
- Lead developer
- Solvonis Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**SVNS-001** is an investigational medication-assisted treatment for severe alcohol use disorder consisting of intravenous racemic ketamine administered alongside proprietary, manualized relapse-prevention cognitive behavioral therapy. Formerly known as AWKN-001, it was renamed SVNS-001 after Solvonis acquired Awakn Life Sciences in May 2025. The program is being evaluated in the UK MORE-KARE Phase 3 study, led through the University of Exeter Clinical Trials Unit, to reduce heavy drinking and support abstinence. ([markets.ft.com](https://markets.ft.com/data/announce/full?dockey=1323-17056573-73NKEJ8J6L2AI6CQ89R4E05LNL))
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on SVNS-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVNS-001.